Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer-Reference-Cited by-同舟云学术

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

Published:2010-12 Issue:12 Volume:21 Page:2305-2315
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Chan A.,Miles D.W.,Pivot X.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/12/2305/499426/mdq122.pdf

Reference64 articles.

1. National Comprehensive Cancer Network. NCCN Guidelines 2009 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (9 July 2009, date last accessed)

2. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;Kataja;Ann Oncol,2008

3. Third consensus on medical treatment of metastatic breast cancer;Beslija;Ann Oncol,2009

4. A systematic review of taxane-containing regimens for metastatic breast cancer;Ghersi;Br J Cancer,2005

5. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer;Piccart-Gebhart;J Clin Oncol,2008

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Review of Taxane Treatment in Breast Cancer: Clinical Perspectives and Toxicity Profiles;Cureus;2024-04-29

2. Bevacizumab-induced proteinuria and its association with antihypertensive drugs: A retrospective cohort study using a Japanese administrative database;PLOS ONE;2023-08-10

3. Upregulated HMGB3 resulting in the poor prognosis of lung adenocarcinoma by activating stromal angiogenesis through immune microenvironment;2023-06-02

4. Upregulated HMGB3 resulting in the poor prognosis of lung adenocarcinoma by activating stromal angiogenesis through immune microenvironment;2022-12-19

5. Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits;Journal of Bone Oncology;2022-06